“The Tesla and SpaceX CEO sent an email to employees at both companies on Tuesday saying everyone must spend 40 hours per week in the office. ‘If you don’t show up, we will assume you have resigned. The more senior…
COMMENTARY
SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
The Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) was established as Japan’s vaccine R&D control tower within the Japan Agency for Medical Research and Development (AMED) on March 22. To prepare for infectious…
To read the full story
Related Article
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- Govt Council OKs Draft Policy to Strengthen Vaccine R&D, Establish SCARDA
March 1, 2022
- AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
May 26, 2021
COMMENTARY
- Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
- New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
June 2, 2022
- Foreign Pharma Growing Vocal against Japan’s Pricing Policy, Flags Return of Drug Lag
May 10, 2022
- Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
- Drug Makers Forced to Make Tough Decisions on AG Strategies: Licensing Profits or Losses on Early G1 Cuts?
April 8, 2022
Pharma companies have seen Japan’s new “zero” premium coefficient rule extensively applied to medicines with low cost disclosure ratios since its introduction under the drug pricing reform this April. Of new drugs listed in the past two months, all six…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…